Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy by Pereira, Maria Luiza Saraiva et al.
ARTICLE OPEN ACCESS
Intragenic variants in the SMN1 gene determine
the clinical phenotype in 5q spinal muscular
atrophy
Rodrigo de Holanda Mendonça, MD, Ciro Matsui, Jr., MD, Graziela Jorge Polido, PT,
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The aim of the study was to report the proportion of homozygous and compound heterozygous variants
in the survival motor neuron 1 (SMN1) gene in a large population of patients with spinal muscular
atrophy (SMA) and to correlate the severity of the disease with the presence of specific intragenic variants
in SMN1 and with the SMN2 copy number.
Methods
Four hundred fifty Brazilian patients with SMA were included in a retrospective study, and clinical data
were analyzed compared with genetic data; the SMN2 copy number was obtained by multiplex ligation-
dependent probe amplification and pathogenic variants in SMN1 by next-generation sequencing.
Results
Four hundred two patients (89.3%) presented homozygous exon 7-SMN1 deletion, and 48 (10.7%) were
compound heterozygous for the common deletion in one allele and a point mutation in the other allele.
Recurrent variants in exons 3 and 6 (c.460C>T, c.770_780dup and c.734_735insC) accounted for almost
80% of compound heterozygous patients. Another recurrent pathogenic variant was c.5C>G at exon 1.
Patients with c.770_780dup and c.734_735insC had a clinical phenotype correlated with SMN2 copy
number, whereas the variants c.460C>T and c.5C>G determined a milder phenotype independently of
the SMN2 copies.
Conclusions
Patients with specific pathogenic variants (c.460C>T and c.5C>G) presented a milder phenotype, and
the SMN2 copy number did not correlate with disease severity in this group.
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Spinal muscular atrophy (SMA) is a neurodegenerative disease
of lower motor neurons, leading to progressive weakness as-
sociated with ventilatory insufficiency. The most common
form of SMA is caused by mutations in the survival motor
neuron 1 (SMN1) gene located at 5q13.1 Exon 7 of SMN1 is
not detectable in approximately 96% of patients with SMA, and
approximately 4% of patients have a combination of the de-
letion and an intragenic mutation in the second allele.1,2 The
centromeric homologous SMN2 gene cannot compensate for
the SMN1 defect because a single nucleotide polymorphism
located in exon 7 causes exon skipping in about 90% of SMN2
transcripts leading to a nonfunctional SMN protein.3
The SMN2 copy number varies, and several studies have
demonstrated a strong correlation between the number of
SMN2 copies and SMA severity.4–6 However, other genetic
and environmental factors also influence the clinical severity
of the disease. One example is the variant c.859G>C in exon 7
of SMN2, which acts as a positive modifier that results in an
approximate 20% increase in full-length SMN RNA.7,8 In
addition, intragenic mutations in SMN1may contribute more
significantly to clinical severity than SMN2 copy numbers in
some patients with SMA.9
The aim of this study was to determine the proportion of ho-
mozygous and compound heterozygous deletions in the SMN1
gene in a Brazilian population of patients with SMA and to
correlate the severity of the disease with the presence of specific
intragenic variants in SMN1 and with the SMN2 copy number.
Methods
A national collaborative historical cohort study was conducted
to describe the clinical and molecular features of consecutive
patients with SMA referred to 12 neuromuscular centers in
Brazil, from January 2016 to July 2019. The eligibility criterion
was the presence of SMN1 mutations in patients with the
SMA phenotype. General and clinical data of the patients
were obtained through the records including age at birth, age
at onset, SMA subtype, ventilatory status, use of gastrostomy,
and sitting, standing, and walking capacity.
All patients fulfilled the diagnostic criteria of proximal SMA
defined by the International SMA Consortium and were
classified into the 5 main clinical phenotypes of SMA, from
0 to 4.10,11 All patients had a genetic confirmation of SMN1
gene mutation in both alleles. DNA used in the analysis was
extracted from leukocytes from peripheral blood or from oral
swab. Copy number variation in the SMN1 and SMN2 genes
was detected by the multiplex ligation-dependent probe
amplification (SALSA MLPA kit P060-SMA, MRC Holland)
method for both SMN1 and SMN2. Patients who failed to
show homozygous absence of SMN1 exon 7 by MLPA were
submitted to sequencing of SMN1/SMN2 genes by next-
generation sequencing (NGS). The methodology used was
exon capture with Agilent Mendelics Custom Panel V3 fol-
lowed by sequencing with Illumina HiSeq.
Sequence variations were compared with data available in
the Human Gene Mutation Database and ClinVar with
reference to the GRCh37 version of the human genome.
Variants were classified according to the 2015 American
College of Medical Genetics and Genomics criteria.
PolyPhen-2, Sorting Intolerant From Tolerant, Combined
Annotation Dependent Depletion, Mendelian Clinically
Applicable Pathogenicity score, MutationTaster, Human
Splicing Finder v3.0, and ESEfinder v.3.0 were used for in
silico analysis. Phylogenetic conservation was estimated with
Genomic Evolutionary Rate Profiling, and allele frequencies
were searched on the Genome Aggregation Database and
the 1000 genomes browser.
Standard protocol approvals, registrations,
and patient consents
The study was approved by the institutional ethics commit-
tees of the local centers. Informed consent was obtained for
genetic studies from the patients or their legal representatives.
Data availability
Data corresponding to the total number of patients, distri-
bution in SMA types, distribution of the variants in SMN1,
and SMN2 copy number are available in figures 1–4. In-
dividual details of heterozygous patients are fully shown in
table 1. Any data not published within the article are available
in a public repository. Methods and the statistical plan are also
fully reported in the Methods section. Details regarding the
statistical analysis by logistic regression are shown in table 2.
Statistical analysis
For descriptive purposes, categorical variables were expressed
as absolute and relative frequencies and then compared with
Pearson χ2 in a univariate analysis. Continuous variables were
expressed as the mean and SD and then compared with the
Student t test. Themild phenotype was defined as SMA type 3
or 4. To identify factors associated with SMA phenotypes
(sex, SMN2 copy number, and specific intragenic variants),
Firth logistic regression analysis was performed for the het-
erozygous patients. The significant variables at the 0.10 level
in the univariate analysis were included on the multivariate
model. The results were expressed as odds ratios, coefficients,
and 95% confidence intervals.
Glossary
MLPA = multiplex ligation-dependent probe amplification; NGS = next-generation sequencing; SMA = spinal muscular
atrophy; SMN1 = survival motor neuron 1.
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All tests were 2 tailed, and final p values less than 0.05 were
considered to be statistically significant. All analyses were
performed with Statistical Package for Social Sciences soft-
ware, version 20 (SPSS, IBM Statistics, Chicago, IL).
Results
A total of 450 patients with SMA with genetic confirmation
were identified. Among them, 105 (23.3%) were classified as
type 1 (3 of them were SMA type 0/1a), 153 (34%) as type 2,
183 (40.7%) as type 3, and 9 (2%) as type 4 (figure 1). Of the
patients, homozygous deletion of SMN1 exon 7 was detected
in 402 (89.3%), and 48 patients (10.7%) had 1 nondeleted
allele of SMN1 exon 7 with an intragenic variant (figure 2). No
patient was homozygous for intragenic variants. The quanti-
fication of the SMN2 copy number was possible in all 450
patients tested by MLPA.
Within the group of 48 compound heterozygous patients, 10
(20.8%) were type 1, 11 (22.9%) type 2, 22 (45.8%) type 3,
and 5 (10.5%) type 4 (figure 1).
As expected, the SMN2 copy number presented an inverse
correlation with the severity of phenotype in the homozygous
group. A greater proportion of patients with SMA type 1
carried 2 copies of SMN2 (72.5%), most patients with SMA
type 2 had 3 copies (65%), and patients with type 3 presented
3 or 4 copies of SMN2 (69.6% and 30.5%, respectively)
(figure 3).
A total of 7 different pathogenic variants were identified in
SMN1/SMN2 (figure 2 and table 1), 4 of which were recurrent
variants. The most frequent variant was the c.460C>T
(p.Gln154*). This variant was identified in 16 patients and has
not been previously reported in the literature; its allelic fre-
quency in large databases (Genome Aggregation Database and
Exome Aggregation Consortium) is zero, indicating that it is a
pathogenic variant. The variant c.770_780dup (p.Gly261-
Leufs*) was identified in 13 patients, the variant c.5C>G
(p.Ala2Gly) in 9 patients and the variant c.734_735insC
(p.Pro246Thrfs*) in 7 patients. General clinical data of the
compound heterozygous patients are presented in table 1.
In the group of compound heterozygous patients, we did not
find the variants c.859G>C and A-44G that are considered
positive modifiers.7,8,12 In these patients, it was possible to
state that the variant c.859G>C was not detected because in
our database, there are controls with this variant identified
using the same NGS methodology. Because of methodolog-
ical limitation, intragenic variants A-549G and C-1897T were
not analyzed. All variables that were classically associated with
disease severity (sex and SMN2 copy number), along with
pathogenic variants that showed statistical significance (p <
0.05) in correlation with the phenotype in the univariate
analysis, were included in the multivariate logistic regression
analysis model (table 2). Although all patients carrying the
variant c.5C>G presented as SMA type 2 or 3, we did not find
a statistical significance association with the mild phenotype
in the univariate analysis (p = 0.71), so these patients were not
included in the multivariate analysis. In heterozygous patients,
no clear correlation existed between the clinical phenotype
and the SMN2 copy number (p = 0.498). However, as occurs
in homozygous patients, the male sex showed an association
with a more severe phenotype (p = 0.041). Several hetero-
zygous patients with type 2 or 3 SMA carried only 1 SMN2
copy, and most patients with types 3 and 4 SMA carried 2
copies (figure 4). In these patients, we could demonstrate by
logistic regression that the most important factor in de-
termining the phenotype was the pathogenic variant that the
patients presented, with variant c. 460C>T related to the mild
phenotype (p = 0.014), whereas variants c.770_780dup and
c.734_735insC were related to more severe phenotypes
depending on SMN2 copy number (tables 1 and 2). Although
the variant c.5C>G was not entered in the multivariate
Figure 1 Prevalence of types of SMA
Prevalence of types of SMA in the studied population (left
chart) compared with the prevalence of SMA types in
heterozygous patients (right chart). Note the significant
increase in the proportion of patients with mild pheno-
types (types 3 and 4) in the heterozygote group. SMA =
spinal muscular atrophy.
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1 c.460C>T/p.Gln154*/exon 3 3 1 M/39 2 y No Wheelchair/36 y
2 3 4 M/38 6 y No Walking
3 3 3 M/32 13 y No Wheelchair/21 y
4 3 1 M/30 2 y No Wheelchair/11 y
5 3 2 F/29 6 y No Wheelchair/12 y
6 3 2 M/26 5 y No Wheelchair/18 y
7 3 3 M/26 8 y N BIPAP Wheelchair/17 y
8 3 2 M/19 6 y No Walking with assistance
9 3 2 M/18 13 y No Walking
10 3 2 M/16 4 y No Walking with assistance
11 3 2 F/14 2 y No Walking with assistance
12 3 3 F/14 4 y No Walking with assistance
13 4 2 M/40 18 y No Wheelchair/32 y
14 4 2 F/39 18 y No Walking
15 4 2 F/30 25 y No Walking
16 4 2 M/19 16 y No Walking
17 c.770_780dup/p.Gly261Leufs*8/
exon 6
1 2 F/11 1 mo IV Nonsitter
18 1 2 F/died 1 y 5
mo
1 mo IV Nonsitter
19 1 2 M/died 1 y
6 mo
5 mo IV Nonsitter
20 1 2 F/1 y 6 mo 3 mo IV Nonsitter
21 1 2 F/died 9
mo
3 mo IV Nonsitter
22 2 2 F/34 1 y No Wheelchair
23 2 2 F/19 8 mo N BIPAP Wheelchair
24 2 3 M/12 11 mo No Wheelchair
25 2 3 M/8 1 y 5 mo No Wheelchair
26 2 3 F/4 7 mo No Wheelchair
27 3 3 F/18 1 y 6 mo No Wheelchair/7 y
28 3 3 F/13 2 y No Wheelchair/11 y
29 4 4 F/39 26 y No Walking
30 c.5C>G/p.Ala2Gly/exon 1 2 1 M/12 7 mo N BIPAP Nonsitter
31 2 1 M/died 9 y 1 y 2 mo IV Nonsitter
32 2 1 M/9 9 mo IV Nonsitter
33 3 1 F/23 11 y No Wheelchair/21 y
34 3 1 M/20 5 y No Walking with assistance
35 3 1 F/19 3 y N BIPAP Wheelchair/11 y
36 3 1 F/12 1 y 5 mo IV Wheelchair/4 y
Continued
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analysis, based on the model criteria, all patients with this
variant had 1 SMN2 copy, but none of them had type 1 SMA,
which one may expect.
Discussion
We report on the largest cohort of patients with SMA in Latin
America and bring new insights regarding the molecular di-
agnosis in SMA. The presence of compound heterozygous
mutations occurred in approximately 10.7% of the patients
with SMA, a frequency higher than that reported in the lit-
erature. This fact draws attention to our population, especially
with the future advent of neonatal screening for the diagnosis
and treatment of presymptomatic patients. Patients with
milder phenotypes tend to have a compound heterozygous
genotype more often than patients with type 1 SMA, and in
our study, the frequency of type 1 SMA was lower than
commonly reported in the literature10, most probably related
to the higher mortality in this group of patients. More in-
teresting is the finding that most of the patients with SMA
type 4 (55.5%) were compound heterozygous, most of them
carrying the same variant (p.Gln154*). These data reinforce
the idea that diagnosis in SMA type 4 is more difficult even
from the molecular point of view, and the average time from
symptom onset to diagnosis in this group was 10 years,
ranging from 2 to 18 years (data not shown in table).
Knowledge of the molecular portrait of the population is
important to understand the clinical profile and natural his-
tory of patients and to assist in the therapeutic planning,
Table 2 Multivariate analysis identifying factors associated with mild phenotype (SMA types 3 and 4) in heterozygous
patients (n = 48)
Variables Coefficient SE Chi square Odds ratio 95% CI p Value
Sex (male) −1.960 1.091 4.174 0.14 −4.55 to −0.07 0.041
SMN2 copy number 0.466 0.689 0.460 1.59 −0.84 to 1.98 0.498
c.460C>T 3.288 1.682 6.022 26.78 0.58 to 8.33 0.014
c.770_780dup −2.731 1.456 4.642 0.06 −6.10 to −0.22 0.031
c.734_735insC −3.010 1.586 4.895 0.04 −6.61 to −0.31 0.027
Abbreviations: CI = confidence interval; SE = standard error; SMA = spinal muscular atrophy.
















37 3 1 F/7 1 y 6 mo No Walking
38 3 1 F/6 3 y No Wheelchair/6 y
39 c.734_735insC/
p.Pro246Thrfs*10/exon 6
1 2 F/13 4 mo IV Nonsitter
40 1 2 F/8 4 mo IV Nonsitter
41 1 2 F/1 4 mo N BIPAP Nonsitter
42 1 2 M/1 2 mo N BIPAP Nonsitter
43 2 3 M/17 7 mo N BIPAP Wheelchair
44 2 3 F/4 6 mo No Wheelchair
45 3 3 F/27 2 y No Wheelchair/21 y
46 c.469C>T/p.Gln157*/exon 3 2 3 F/25 1 y 6 mo No Wheelchair
47 c.806T>C/p.Met269Thr/exon 6 3 1 M/14 5 y No Wheelchair/13 y
48 c.346A>T/P.Ile116Phe/exon 3 1 2 M/died 11
mo
3 mo IV Nonsitter
Abbreviations: IV = invasive ventilation and tracheostomized; N BIPAP = night BIPAP use; Pt = patient; SMA = spinal muscular atrophy.
a At last evaluation.
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considering that part of the currently available specific ther-
apies modulate the SMN2 gene expression.13 The correlation
between the copy number of the SMN2 gene and the phe-
notype followed a similar pattern to that reported in the
literature,4–6 as patients with SMA type 1 usually carried 2
copies, whereas type 2 patients usually carried 3 copies and
types 3 and 4 presented with 3 or 4 copies. As reported in the
literature, such a correlation is not strict because to a lesser
extent, patients with SMA type 1 had 3 copies and type 3 and
4 phenotypes had 2 copies.4,5 The lack of exact correlation
must be related to other phenotypic modifiers, such as the
presence of the variants c.859G>C in exon 7 and A-44G,
A-549G, and C-1897T in intron 6 of SMN2 that act as positive
modifier.7,8,12 Analysis of these variants in the SMN2 gene was
not performed in our homozygous patients, and in the group
of compound heterozygous patients, we did not find the
variants c.859G>C and A-44G.
We identified 4 recurrent variants in our population: 3 non-
sense and 1 missense variants. The most common variant
identified was c.460C>T, located at exon 3, that creates a
premature stop codon at residue 154 (p.Gln154*). Exon 3 is
responsible for encoding the tudor domain of protein, which
interacts with a complex of Sm proteins, kaolin, fibrillarin, and
ribonucleoproteins.14 This information confirms that exon 3
is a hot spot for small mutations; in addition, it supports the
Figure 3 Correlation between clinical phenotype of homozygous SMA patients X SMN2 copy number
Correlation between clinical phenotype of SMAX SMN2 copy
number in patients (%) with homozygous deletion of SMN1
detected by MLPA (n = 402). Data from SMA type 0 are not
shown, as all 3 patients carried only 1 SMN2 copy. SMA =
spinal muscular atrophy.
Figure 2 Characterization of SMN1 mutations in the Brazilian population
Among 450 patients with SMA, 402 (89.3%) had a homozygous deletion in exon 7, whereas 48 (10.7%) retained 1 copy of the SMN1 gene with point mutations,
most of them localized at exons 1, 3, and 6. SMA = spinal muscular atrophy; SMN1 = survival motor neuron 1; YG = YG domain.
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importance of the tudor domain for SMN functioning.15,16
This variant was the most common variant in our population,
suggesting a founder effect by a common ancestor. More
detailed ancestral haplotype studies would be needed to
confirm this hypothesis.
Among the 16 patients with this variant, 9 were still walking
(table 1), and of those patients who lost the ability to walk, the
mean age of gait loss was 19 years (11–36 years), compatible
with an SMA type 3b phenotype.11 Of interest, all patients
presented a milder phenotype (SMA types 3 and 4) even in
the presence of 1 or 2 copies of SMN2. There is no clear
explanation for the milder phenotype in this situation. Sossi
et al.17 reported patients with mutations in exon 3 of SMN1
leading to premature termination codons and skipping of the
entire exon generating in-frame transcripts and a better phe-
notype. However, many studies have shown severe missense
mutations occurring in exon 3 that cause severe phenotypes
and thus confirming that amino acids and the tudor domain
located at exon 3 are essential to SMN function.15,16,18–20 A
possibility to explain the milder phenotype associated with the
c.460C>T is the presence of positive modifier variants in
SMN2. The presence of the variants c.859G> C and A-44G
was negative in these cases; however, we cannot exclude the
possibility that other untested modifier variants are involved
in the modulation of the clinical phenotype.
The second most common variant was c.770_780dup
(p.Gly261Leufs*), located at exon 6, and has been previously
reported to be associated with SMA.19,21,22 Parsons et al.21
showed through real-time PCR that the 11-bp duplication in
exon 6 was associated with the SMN1 locus and not SMN2
and was sufficient to produce a severe type 1 SMA phenotype.
In a Portuguese SMA population, this variant was the most
frequent intragenic mutation in a total of 14 heterozygous
unrelated patients, which leads to the hypothesis that this
mutation migrated from the Portuguese population to Bra-
zil22. In our study, as in an SMA Portuguese population study,
all patients carrying this variant exhibited a strict correlation
between the phenotype and the SMN2 copy number, with
patients with 2 SMN2 copies presenting as SMA type 1, pa-
tients with 3 copies presenting as SMA type 2 or 3, and a
patient with a very mild phenotype (SMA type 4) with the
presence of 4 SMN2 copies (table 1).
The third most common variant was the missense c.5C>G
(p.Ala2Gly), located at exon 1. This variant was first reported in
3 patients with SMA, all of whomhad only 1 SMN2 copy, and 2
of whomhad amild phenotype (type 3 SMA).18More recently,
3 additional patients with this variant, a mild phenotype and
only 1 SMN2 copy were also reported.23 Another mutation in
the same location, the p.Ala2Val variant, has already been de-
scribed, and all patients had only 1 SMN2 copy with a mild
phenotype (type 3 SMA).9 Thus, in the presence of this variant,
the SMN2 copy number did not correlate with the phenotype.
The mutation effect of p.Ala2Val, as well as p.Ala2Gly, appears
to be much less deleterious.
A deleterious effect of the c.5C>G variant has been demon-
strated in an SMA mouse model, although the mutation did
not produce a total loss of protein function.24 The authors
reported that in the absence of the SMN2 gene, the transgenic
SMN c.5C>G mutant is unable to rescue the embryonic le-
thality, but in its presence, the c.5C>G transgene delays the
onset of motor neuron loss, resulting in mice with mild SMA.
They concluded that only in the presence of low levels of full-
length SMN is the c.5C>G transgene able to form partially
functional higher-order SMN complexes essential for its
Figure 4 Correlation between clinical phenotype of compound heterozygous SMA patients X SMN2 copy number
Correlation between clinical phenotype X SMN2 copy number
in patients with specific intragenic variants (n = 48). *All pa-
tients with SMA type 1 presented with variants c. 770_780dup
or c.734_745insC and carried 2 copies of SMN2. **Most pa-
tients with SMA types 2 and 3 carrying only 1 SMN2 copy
presented the c.5>G variant. ***The variant c.460C>T was
present inmost patients with SMA types 3 or 4 carrying only 2
copies of SMN2. SMA = spinal muscular atrophy.
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functions, demonstrating the importance of SMN levels in
SMA, even if the protein is expressed from a mutant allele.24
Similarly, in Brazilian patients carrying this variant, none pre-
sented a severe phenotype of the disease, such as type 0 or 1,
even in the presence of only 1 SMN2 copy. Patients presented
with type 2 or 3 SMA with a typical age at disease onset (table
1). Of interest, 3 patients with this variant were in need of
continuous invasive ventilation before age 10 years, which
would not be expected due to the disease duration presented by
patients. This may represent a phenotypically characteristic
effect of the c.5C>G variant on this population, although de-
ficient respiratory care in our population cannot be ruled out.
The last recurrent variant identified in our population was
c.734_735insC (p.Pro246Thrfs*). This variant was not pre-
viously reported in the literature as a recurrent variant in pa-
tients with SMA. As occurs with the c.770_780dup variant, this
mutation is located at exon 6, and all patients carrying this
variant also exhibited a strict correlation between the pheno-
type and the SMN2 copy number. These data lead us to sup-
pose that this mutation severely compromises protein function
at the YG domain of interaction with protein Gemin3.25 Ac-
cordingly, the clinical phenotype of those patients appears to be
dependent exclusively on the SMN2 copy number.
Our study has some limitations as it was a retrospective study,
and there was a bias of survival because the most severe cases
(SMA type 1) had a low prevalence in our cohort. Another
limitation is that NGS cannot distinguish whether pathogenic
variants are located in SMN1 or SMN2, although it is a reliable
test that can be used in real life. The large number of patients
with intragenic small variants identified in our population
could be explained by the current access to the large-scale
sequencing of SMN genes, especially for patients with clinical
features of SMA but negative in the MLPA assays.
We report a large cohort with important findings, such as a
higher frequency of compound heterozygous patients with
SMA in the Brazilian population than reported in the litera-
ture. Most of these patients have a milder phenotype, and the
SMN2 copy number did not correlate well with the severity of
disease, as observed in patients with homozygous deletion in
SMN1 exon 7. The result of our study indicates a specific
point mutation spectrum in the Brazilian population and may
help in the search for an early diagnosis in the era of therapies,
especially in newborn screening. Variants in exons 3 and 6
(c.460C>T, c.770_780dup, c.734_735insC, c806T>C, and
c.346A>T) accounted for almost 80% of our patients. In pa-
tients with exon 7 deletion in 1 SMN1 allele, analysis of exons
3 and 6 should be prompt, as it seems to be a specific hot spot
for small mutations and should be sequenced first. If the
patient presents with mild phenotype and only 1 copy of
SMN2, a search for the c.5C>G variant at exon 1 should be
performed.
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